0

Efficacy of oral micronized progesterone in the treatment of luteal phase defects

Frishman GN et al., 1995

The Journal of reproductive medicine, 40(7), 521-524

PMID 7473442 Source

Abstract

Objective

Vaginal progesterone suppositories are an accepted treatment for infertility attributed to luteal phase defects. Although oral micronized progesterone may be preferable to suppositories for many patients, there are no studies on its use for patients with luteal phase defects. This study evaluated the efficacy of oral micronized progesterone for the treatment of luteal phase defects.

Study design

Seven women with luteal phase defects previously corrected by vaginal suppositories were administered oral micronized progesterone (200 mg by mouth three times a day). Endometrial biopsies were performed to evaluate treatment efficacy. Questionnaires were used to assess side effects, including sedation.

Results

On oral micronized progesterone, all patients had in-phase endometrial biopsies. Despite complaints of drowsiness, the majority of patients preferred the oral formulation over the vaginal route of administration.

Conclusion

We conclude that oral micronized progesterone is efficacious in the treatment of luteal phase defects.

Topics

Reproductive Endocrinology > Luteal Phase > SupportReproductive Endocrinology > Progesterone > SupplementationInfertility > Female Factor > Ovulatory Dysfunction
oral micronized progesterone luteal phase defect, progesterone capsules luteal support, oral progesterone endometrial biopsy, oral vs vaginal progesterone luteal phase, micronized progesterone dosing luteal defect, progesterone side effects drowsiness, oral progesterone patient preference, luteal phase defect treatment progesterone, progesterone by mouth infertility, endometrial dating progesterone supplementation

Cite this article

Frishman, G. N., Klock, S. C., Luciano, A. A., & Nulsen, J. C. (1995). Efficacy of oral micronized progesterone in the treatment of luteal phase defects. *The Journal of reproductive medicine*, *40*(7), 521-524.

Keywords

Administration, Oral, Capsules, Female, Humans, Luteal Phase, Pessaries, Progesterone, Treatment Outcome

Related articles